Cerebral Microbleeds and Thrombolysis Outcomes

Cerebral microbleeds are small deposits of blood breakdown products visible on specialised MRI sequences, reflecting fragile small vessels often affected by hypertension or amyloid angiopathy. Intravenous thrombolysis with tissue plasminogen activator has transformed acute ischaemic stroke care by restoring perfusion but carries a risk of intracerebral haemorrhage. The presence, number and distribution of microbleeds raise important questions about individual bleeding risk and long-term functional recovery. Emerging evidence suggests that high microbleed burden may elevate the chance of haemorrhagic complications without negating overall benefit in most patients. Risk stratification now incorporates markers of small-vessel disease such as white matter hyperintensities and lacunes alongside microbleeds. This integrated approach aims to optimise decision-making, balancing the urgent need for reperfusion against the potential for symptomatic intracranial bleeding. Enhanced imaging protocols and predictive models promise more personalised assessment of thrombolysis safety and efficacy worldwide.

Research from Nature Portfolio

An analysis of patients undergoing endovascular reperfusion found that increasing cerebral microbleed burden on pretreatment MRI was associated with higher rates of post-procedure haemorrhagic complications and poorer three-month functional outcomes. Mediation modelling indicated that this effect was partly driven by small-vessel disease burden, the degree of haemorrhagic transformation and lower rates of successful reperfusion, highlighting how underlying vessel pathology, bleeding risk and recanalisation success interact to shape clinical recovery.

Cerebral Microbleeds and Thrombolysis Outcomes publication trend

The graph below shows the total number of articles in cerebral microbleeds and thrombolysis outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Cerebral microbleeds: Small focal deposits of haemosiderin seen on susceptibility-weighted or T2* MRI, indicating prior microhaemorrhages and vessel fragility.

Intravenous thrombolysis: Systemic infusion of plasminogen activators to dissolve thrombi in acute ischaemic stroke.

Hemorrhagic transformation: Spectrum of bleeding events after reperfusion therapy, ranging from minor petechial haemorrhages to large parenchymal haematomas.

White matter hyperintensities: Areas of increased signal on T2-weighted MRI reflecting chronic small-vessel damage and demyelination.

Small-vessel disease: Pathology affecting small cerebral arterioles and capillaries, including arteriolosclerosis and amyloid angiopathy, that predisposes to microbleeds and white matter changes.

References

1. Cerebral microbleeds shouldn’t dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage. BMC Neurology (2018).
2. Influence of cerebral microbleeds on mechanical thrombectomy outcomes. Scientific Reports (2022).
3. Neuroimaging Markers of Cerebral Small Vessel Disease on Hemorrhagic Transformation and Functional Outcome After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience (2021).
4. New Remote Cerebral Microbleeds on T2*-Weighted Echo Planar MRI After Intravenous Thrombolysis for Acute Ischemic Stroke. Frontiers in Neurology (2022).